

25 **Abstract**

26 **Background:** The 15q13.3 microdeletion has pleiotropic effects ranging from 27 apparently healthy to severely affected individuals. The underlying basis of the variable 28 phenotype remains elusive.

29 **Methods:** We analyzed gene expression using blood from 3 individuals with 15q13.3 30 microdeletion and brain cortex tissue from 10 mice Df[h15q13]/+. We assessed differentially 31 expressed genes (DEGs), protein-protein interaction (PPI) functional modules, and gene 32 expression in brain developmental stages.

33 **Results:** The deleted genes' haploinsufficiency was not transcriptionally compensated, 34 suggesting a dosage effect may contribute to the pathomechanism. DEGs shared between 35 tested individuals and a corresponding mouse model show a significant overlap including 36 genes involved in monogenic neurodevelopmental disorders. Yet, network-wide 37 dysregulatory effects suggest the phenotype is not caused by a singular critical gene. A 38 significant proportion of blood DEGs, silenced in adult brain, have maximum expression 39 during the prenatal brain development. Based on DEGs and their PPI partners we identified 40 altered functional modules related to developmental processes, including nervous system 41 development.

42 **Conclusions:** We show that the 15q13.3 microdeletion has a ubiquitous impact on the 43 transcriptome pattern, especially dysregulation of genes involved in brain development. The 44 high phenotypic variability seen in 15q13.3 microdeletion could stem from an increased 45 vulnerability during brain development, instead of a specific pathomechanism.

46 Keywords: 15q13.3; Copy number variants; Transcriptomics; Protein-protein 47 interaction networks; Nervous System Development.

48 **Introduction**

49 Individuals with 15q13.3 microdeletion (OMIM #612001) show clinical 50 manifestations ranging from no obvious symptoms to severe intellectual disability, 51 neuropsychiatric disorders, and epilepsy $¹$ (Fig. 1 A, B). The most common 15q13.3 deletion</sup> 52 spans 2 Mb and includes eight RefSeq genes (*CHRNA7*, *FAN1*, *TRPM1*, *KLF13*, *OTUD7A*, 53 *MTMR10*, *ARHGAP11B*, and *MIR211*, Fig. 1A)². Many functional and association studies 54 inquired which gene(s) encompassed by the deleted region could be responsible for the 55 phenotype. However, the results were as variable as the clinical manifestation and different 56 groups proposed multiple candidates (*CHRNA7*^{3,4}, *OTUD7A*^{5,6}, *FAN1*⁷, *ARHGAP11B*⁸, *TRPM1*⁹, *KLF13*¹⁰), to explain the symptoms (Fig. 1A). A mouse model of the 15q13.3 58 microdeletion syndrome (Df[h15q13]/+) shows manifestations similar to affected humans 59 ranging from attention deficits to impaired behavior and disrupted prefrontal cortex 60 . processing $\frac{11}{1}$. Thus, the microdeletion effect is stable across species and clearly impairs 61 nervous system function.

62 Recently, it was suggested that many disrupted biological pathways such as Wnt 63 signaling or ribosome biogenesis may be involved in the molecular mechanism underlying the 64 disease rather than singular dosage-affected genes $\frac{12}{2}$. While Zhang *et al.* used a multiomics 65 approach to identify perturbed biological processes, the multiple employed analyses showed 66 disagreement with respect to the pathomechanism. Also, no shared dysregulated genes were 67 identified between human induced pluripotent stem cells (iPSCs) and mouse cortex 12 . This 68 could be a result of the *in vitro* setup and neuronal differentiation protocols, which generally 69 impact gene expression profiles 13 . We thus sought to inquire gene expression profiles in 70 subjects with 15q13.3 microdeletion in a native/*in vivo* state.

71 One major challenge of transcriptomics in a clinical setting is tissue-specific gene 72 expression $14,15$ and the fact that most of the times the only accessible tissue to probe is blood 73 ¹⁶. In our previous work we showed, however, that known genes for neurodevelopmental 74 disorders are not necessarily expressed in the adult brain and that genes which are relevant 75 during embryonic development of the central nervous system can be silenced at a later 76 timepoint ¹⁴. Thus, although not regarded as a representative tissue, blood transcriptomics has 77 the potential to reveal aspects missed in other tissues or iPSCs.

78 In the present study, we analyzed the changes in gene expression profiles in the blood 79 of three individuals with heterozygous microdeletion 15q13.3 and intellectual disability 80 associated with epilepsy. We identified a significant overlap (*p*-value = 0.02) of 68

81 differentially expressed genes (DEGs) between humans and mouse $(Df[h15q13]/+)$ cortex. 82 The gene ontology (GO) category most significantly enriched with DEGs was "nervous 83 system development–GO:0007399" and DEGs in blood, which are not expressed in the adult 84 brain, revealed maximum expression levels in the prenatal stage of brain development. The 85 disrupted gene expression profile could lead to an increased vulnerability in the early stages 86 of nervous system development.

87 **Materials and Methods**

88 *Ethics approval*

89 This study was approved and monitored by the ethics committee of the University of

90 Leipzig, Germany (224/16-ek and 402/16-ek).

91 *Chr15q13.2q13.3 microdeletion individuals and mouse model (Df[h15q13]/+)*

92 Three individuals with diagnosed heterozygous 15q13.2q13.3 microdeletions were 93 . previously described 17 . For all individuals we performed Illumina TruSight One Panel and 94 microarray analysis. Patient 1 is a male with a deletion of 2.56 Mbp 95 (15q13.2q13.3(30366247_32927476)x1). The second patient is female and carries a deletion 96 on chromosome 15 of 1.57 Mbp (15q13.2q13.3(30936285_32514341)x1). Patient 3 is a male, 97 has a deletion of 2.14 Mbp on chromosome 15 (15q13.2q13.3(30371774_32514341)x1). He 98 was additionally diagnosed with a maternally inherited splicing-variant in the remaining 99 *TRPM1* allele and a heterozygous *de novo* point mutation in *MITF*. Pathogenic variants in 100 *MITF* gene cause albinism, which was also clinically diagnosed in this individual. His 101 ophthalmological phenotype (severe myopia, astigmatism, and pendular nystagmus) were 102 clinical symptoms of the autosomal recessive TRPM1 phenotype (one allele being deleted as 103 part of the 15q13.3 microdeletion and the other allele carrying the maternally inherited 104 splicing variant). In sum, he suffered from a complex combined phenotype with neurologic 105 symptoms attributed to the 15q13.3 microdeletion. Blood RNA samples were taken from the 106 three individuals (two males and one female, aged 27–63 years) and four control subjects 107 (two males and two females, aged 20–52 years).

108 To identify molecular changes which are consistent across species we used the data 109 generated by Gordon and colleagues (GSE129891)¹⁸. We analyzed transcriptomes from 110 cerebral cortex tissue of mice with heterozygous deletions on mouse chromosome 7qC 111 syntenic to human $15q13.3$ ^{11,18}.

112 *RNA extraction and sequencing*

113 RNA was extracted from PAXgene blood samples using PAXgene Blood RNA Kit 114 (Qiagen). RNA sequencing (RNA-seq) libraries were prepared using TruSeq RNA Library 115 Prep Kit v2 (Illumina, San Diego, CA) and sequenced on an Illumina NovaSeq platform with 116 151 bp paired-end reads.

117 *Differential Gene Expression (DEG) analysis*

118 RNA-seq reads were mapped to the human genome assembly hg38 with STAR 119 (version 2.6.1d) ¹⁹. We computed the transcript levels with htseq-count (version 0.6.0) ²⁰. 120 From GSE129891 we analyzed read counts of ten wild type and ten (Df[h15q13]/+) mouse 121 cerebral cortex samples. Genes with a sum of less than 10 reads in all samples together were 122 excluded from further analysis. Differential expression of genes was determined with the R 123 package DESeq2 (version 1.30.1)²¹, which uses the Benjamini-Hochberg method to correct 124 for multiple testing ²². Genes were considered to be significantly differentially expressed if p -125 adj < 0.05. To check clustering of RNA-sequencing samples of subjects and controls, a 126 principal component analysis (PCA) was performed with the R package pcaExplorer (version $2.6.0$ 23 . RNA count data were variance stabilized transformed and the 500 most variant 128 genes (top n genes) were selected for computing the principal components.

129 *Expression of DEGs in different developmental stages*

130 Expression data of DEGs were obtained from PTEE (version 1.1) ¹⁴ for the adult brain 131 cortex. Genes expressed at a low level in adult brain tissue may be expressed at a higher level 132 in the developing brain and therefore, could still play a significant role in neurodevelopment. 133 Hence, for DEGs expressed <1.5 TPM in adult brain cortex (according to PTEE), expression 134 levels in different developmental stages were obtained from the R package ABAEnrichment 135 (version 1.20.0)²⁴ for the whole brain. We used a Tukey's HSD test to determine whether this 136 group of DEGs (<1.5 TPM in adult brain cortex) displays a significantly different expression 137 profile between the brain developmental stages.

138 DEGs which are expressed <1.5 TPM in adult brain cortex but >1.5 RPKM in prenatal 139 stage of the whole brain and reach their maximum of expression in the prenatal stage were 140 selected and further analyzed for GO enrichment.

141 *DEGs involved in NDDs*

142 A list of genes, which are known to play a role in NDDs, was obtained from PTEE $¹⁴$.</sup> 143 DEGs of 15q13.2q13.3 microdeletion patients were compared to the list of NDD genes, to 144 determine DEGs that could contribute to the neurological symptoms observed in those 145 patients. The significance for enrichment of DEGs with NDD genes was calculated using a 146 binomial test in R 25 .

147 *GO enrichment*

148 Gene ontology enrichment analysis was performed with the R package GOfuncR (version 1.14.0) for up- and down-regulated DEGs 26 . GO nodes with a family wise error rate 150 (FWER) <0.05 were considered significantly enriched. To check for unspecific GO 151 enrichment analysis results, the four control subjects were split in two groups and differential 152 gene expression and GO enrichment analyses were performed for those two control groups.

153 *Identification of activated/inactivated DEG-interacted functional modules*

154 We investigated the activity of DEG-interacted functional modules to elucidate the 155 roles of DEGs in 15q microdeletion. The DEG-interacted network was constructed by the 156 DEGs and their interacting partners in the human protein interaction network (PIN), which 157 was obtained from the InBio Map database 27 . A DEG-interacted functional module is a 158 subnetwork of the DEG-interacted network formed by genes annotated by the same biological 159 processes. The functional annotations of genes were obtained from GO 28,29 , and only the 160 annotations supported by experiments were used in this study. Additionally, to ensure the 161 DEGs' participation and functional association among genes, all the functional modules were 162 required to contain at least one DEG and one interaction. To determine if the member genes 163 of the tested functional module were overrepresented at the top of the entire ranked gene list, 164 we performed the gene set enrichment analysis $(GSEA)$ ³⁰ for evaluating each module's 165 activity and inactivity separately. To assess the activity (inactivity), the entire gene list was 166 ranked downward (upward) by the fold change of genes between the 15q microdeletion and 167 controls. We then calculated the enrichment score (ES) for each functional module by 168 walking down the ranked gene list. The ES of functional module *f* is defined as below:

$$
ES_f = \max(S_i), i \in \{1, ..., N\}
$$

$$
S_i = \sum_{j=0}^{i} p \times \frac{1}{N_f} - (1-p) \times \frac{1}{(N-N_f)}, \text{ where } p = \begin{cases} 0\\ 1, \text{ if gene } i \in f \end{cases}
$$

169 where S_i is the score of gene *i*, *i* is ordered by fold change, N_f is the number of genes in 170 the tested functional module, *N* is the number of total ranked genes, and *p* is a binary 171 parameter. To estimate the significance of ES_f , we produced 1,000 scores ES_{rand} calculated 172 from 1,000 randomly permutated gene lists. Then, we denoted the standard score *z*, which was 173 defined as below, as the activity or inactivity of functional module *f*.

$$
z = \frac{ES_f - \mu}{\sigma}
$$

174 where μ and σ are respectively the mean and standard deviation of 1,000 *ES_{rand}*. 175 Finally, the functional modules possessing *z* of activity greater than two and *z* of inactivity 176 less than zero were defined as activated; and the functional modules with *z* of inactivity 177 greater than two and *z* of activity less than zero were defined as inactivated. The discovered 178 activated or inactivated functional modules were further summarized/clustered by the REVIGO ³¹ algorithm with similarity ≥ 0.9 that was calculated from Resnik ³² algorithm and visualized using the treemap package ³³. visualized using the treemap package 33 .

181 To predict key transcription factors and cofactors that drive transcriptomic differences 182 between microdeletion individuals and controls we used Mining Algorithm for GenetIc 183 Controllers (MAGIC), which leverages ENCODE ChIP-seq data to look for statistical 184 enrichment of transcription factors and cofactors in genes and flanking regions 34 .

185 **Results**

186 *Transcriptional changes in 15q13.3 microdeletion individuals and Df[h15q13]/+ mice*

187 To study the effects of the 15q13.3 microdeletion on transcriptional regulation, we 188 performed RNA-seq from three individuals carrying a heterozygous 15q13.3 microdeletion 189 (Fig. 1) and four control subjects. Further, to identify robust changes across species and 190 tissues, we analyzed cerebral cortex tissue from ten mice (Df[h15q13]/+) reported by Gordon 191 *et al.* ¹⁸. While in the 15q13.3 microdeletion subjects we identified 2,334 genes (adjusted *p*-192 value < 0.05) with altered expression levels compared to controls (Supplementary Table S1), 193 only genes within the deleted region withstood multiple testing correction in the mouse 194 (Supplementary Table S1). This could be related to a difference in synteny between the 195 mouse and human chromosomal regions, to the high interindividual variability of our 196 subjects, or to the generally mild impact on gene expression with genes not reaching the 197 dysregulation threshold necessary to withstand conservative multiple testing correction. The 198 immediate result of applying multiple testing correction is that the probability a true effect 199 may be rejected will increase 35 . To control for false positives, but also to avoid erroneously 200 rejecting real effects we decided to focus on DEGs shared between human and mouse. We, 201 thus, considered genes with uncorrected *p*-value < 0.05 in the mouse and identified 68 shared 202 genes between the two species and different tissues (Supplementary Table S1). To test 203 whether the number of overlapping genes is higher than expected by chance we performed 204 100,000 random samplings considering a total of 20,000 genes. This yielded a *p*-value of 0.02 205 suggesting the overlap is significant. By contrast, when we considered DEGs among controls, 206 only six genes were shared with the (Df[h15q13]/+) mouse model, which is an amount 207 expected to occur by chance (*p*-value=0.94 from 100,000 simulations).

208 To check whether the gene dosage affects gene expression, we identified genes located 209 in the deleted site, which are expressed in blood and brain cortex (Supplementary Fig. S1). 210 Four genes have an expression higher than 1.5 TPMs in brain cortex ¹⁴ (*FAN1*, *MTMR10*, 211 *KLF13*, *OTUD7A*) of which *MTMR10* and *KLF13* are also highly expressed in blood 212 (Supplementary Fig. S1). These genes were significantly downregulated in both human and 213 mouse samples (Supplementary Table S1). Moreover, although *FAN1* and *OTUD7A* display 214 low expression levels in blood (Supplementary Fig. S1), they were also significantly 215 differentially expressed in our blood transcriptome analysis (Supplementary Table S1).

216 We next focused on shared DEGs between 15q13.3 microdeletion individuals and the 217 mouse model. Variants in eight of these genes (*PHIP*, *KAT6A*, *VPS13B*, *GPAA1*, *CHD7*,

218 *FIBP*, *KMT2C*, *AP1S1*) are known causes for monogenic NDD 36 . There are six genes which 219 have a gene ontology (GO) annotation related to gene expression (*ZFP57*, *EDA*, *KAT6A*, 220 *CD46*, *PIK3R3*) and also six genes related to brain development (*CHD7*, *ITGA4*, *MYLIP*, 221 *PAFAH1B3*, *SIRT2*, *B4GALT2*). Interestingly, we could also identify components of the 222 major histocompatibility complex, class II to be dysregulated in both blood and brain 223 (Supplementary Table S1), which may reflect a disturbed inflammatory or immune process.

224 *Molecular pathways affected by transcriptome alterations in 15q13.3 microdeletion*

225 To identify molecular pathways that may be affected by the gene expression profiles 226 we performed GO enrichment analysis followed by protein-protein-interaction (PPI) 227 networks, as previously described $37,38$. Using the mouse data, we identified general GO 228 categories like cellular components or developmental processes to be enriched with DEGs 229 (Supplementary Table S2). For human subjects, there were two less general GO terms which 230 were most significantly enriched with DEGs: "nervous system development" (GO:0007399, 231 *p*-value after family wise error rate (FWER) multiple correction = 0.036) with 32 associated 232 genes and "DNA binding" (GO:0003677, *p*-value FWER multiple correction = 0.046) with 233 183 associated genes (Table 1, Supplementary Table S2).

234 To better delineate molecular pathways, involved in the copy-number variant (CNV) 235 pathomechanism, we further focused on identifying the functional modules formed by DEGs 236 from human subjects and their PPI partners. This revealed that most nodes clustered in 237 cellular processes like metabolic pathways, signaling, or cellular components (Fig. 2, 238 Supplementary Table S2). Since regulation of gene expression appeared to be perturbed, we 239 tested if the gene expression profile matches dysregulation of one or more transcription 240 factors based on ENCODE Chip-seq data 34 . This analysis revealed no significant enrichment 241 for genes associated with a known transcription regulator, suggesting that a single gene 242 cannot explain the observed expression profile. Interestingly, inactivated functional modules 243 clusters are mainly involved in immune response and regulation of gene expression (Fig. 2B, 244 Supplementary Table S2). Oligodendrocyte differentiation and development appear to be 245 affected, which together with the "positive regulation of neuron death" (Fig. 2A, B, 246 Supplementary Table S2) could explain the impaired nervous system development. To check 247 whether those molecular pathways are specifically identified in the microdeletion individuals, 248 we analyzed differential gene expression between two control groups. GO terms significantly 249 enriched with DEGs of the control groups were mostly related to immune response, and to a 250 much lesser extent to gene expression regulation (Supplementary Table S2). Thus, the

251 identification of those molecular pathways in the individuals bearing 15q13.3 microdeletion 252 may not be related to the deleted region, but rather to the analyzed tissue. In contrast, we did 253 not identify any GO terms related to nervous system development in the controls. This 254 supports our hypothesis that the effect on pathways related to nervous system development in 255 the affected individuals is a result of the microdeletion.

256 We showed that affected genes were enriched in pathways related to nervous system 257 development (Table 1) and that PPIs influence apoptosis and neuron death (Fig. 2B). This 258 prompted us to inquire all DEGs that have known Mendelian associations with monogenic 259 NDD. We identified 252 of the DEGs to be related to monogenic intellectual disability (Fig. 260 2C, Supplementary Table S1). The number of genes is significantly higher than expected by 261 chance (*p*-value binomial test = 0.003), which could suggest an underlying polygenic effect 262 that leads to an increased risk for a neurodevelopmental disorder.

263 *Dysregulated genes in 15q13.3 microdeletion individuals expressed in the developing brain*

264 Further, we asked whether blood DEGs, which are not expressed in the adult brain 265 cortex, may have been expressed in the developing brain. We identified 358 DEGs, which are 266 expressed in blood but not in the adult brain. We used the ABAEnrichment package in R 24 to 267 check the expression levels of these genes during the different stages of brain development 268 (Supplementary Table S3). For 245 of the 358 genes, we could retrieve expression levels from 269 the Allen Brain Atlas. Our analysis revealed that for DEGs, which are silenced in the adult 270 brain, there is a significant enrichment for the ones with a maximum expression level in the 271 developing brain (*p*-value = 0.04, Fig. 3). A GO enrichment analysis of the 53 genes showed 272 that several of these genes are involved in chromosome organization during cell division, but 273 also identified the e.g. *DRAXIN* gene to be dysregulated, which is involved in the 274 development of spinal cord (Supplementary Table S3).

275 **Discussion**

276 The 15q13.3 microdeletion is associated with pleiotropic effects and has been 277 described in a wide spectrum of clinical contexts ranging from apparently healthy individuals 278 to some severely affected with ID, epilepsy or even schizophrenia (Fig. 1B) 2 . It is difficult to 279 dissect the mechanisms contributing to the nervous system developmental disturbance mostly 280 because of the limitations of *in vitro* approaches aiming to reproduce human brain 281 development 10 . Thus, the etiology of the 15q13.3 microdeletion's range of hypervariable 282 symptoms remains elusive.

283 To understand how dysregulation of gene expression contributes to 15q13.3 284 microdeletion pathomechanisms, we aimed to circumvent artefacts introduced by 285 conventional *in vitro* approaches. Thus, we analyzed transcriptional profiles from three 286 individuals with 15q13.3 microdeletion in an *in vivo* state in blood, which is an easily 287 accessible tissue. To identify genes, which are robustly dysregulated we additionally analyzed 288 brain cortex tissue from a 15q13.3 microdeletion mouse model.

289 We initially checked for dosage effects of the genes included in the microdeletion 290 (Fig. 1A). This revealed that there are four genes with high expression in brain cortex (Supplementary Fig. S1¹⁴): *FAN1*, *MTMR10*, *KLF13*, *OTUD7A*, all of which showed 292 significant down-regulation in blood (Supplementary Table S1) of our subjects, as well as 293 mouse brain cortex, confirming that a gene dosage effect of the microdeletion contributes to 294 the transcriptional dysregulation. Other genes included in the typical deletion region: *TRPM1*, 295 *CHRNA7*, *MIR211*, *ARHGAP11B*, display low expression levels in brain cortex and blood 296 (Supplementary Fig. S1) and were not significantly differentially expressed in the 15q13.3 297 microdeletion individuals. While *MIR211* is a microRNA, which was not sequenced probably 298 as a result of the library preparation protocol and $ARHGAP11B$ is a human specific gene 36 , 299 *Trpm1* and *Chrna7* were down-regulated in mouse brain cortex (Supplementary Table S1), 300 further supporting the importance of the haploinsufficiency.

301 We next focused on dysregulated genes across the two different tissues in the human 302 subjects and the mouse model. One of the shared down-regulated genes is *CHD7*, which is 303 frequently associated with CHARGE syndrome and has been shown to be highly relevant for 304 neuronal differentiation and brain development ³⁹. *CDH7*, but also other shared dysregulated 305 genes like *KMT2C* and *KAT6A* are involved in chromatin remodeling and hence in regulation 306 of gene expression. This is in accordance with the findings of Zhang *et al*., who described a 307 global epigenomic reprogramming of iPSCs from $15q13.3$ microdeletion individuals 12 . 308 However, in their approach they were not able to identify driving factors, potentially 309 secondary to the bias induced by *in vitro* cultivation. This could also explain why they do not 310 identify any shared dysregulations with the mouse model and their multiomics approach 311 yielded a rather low correlation level among the multiple analyses.

312 To identify affected molecular pathways we performed a GO analysis of DEGs. This 313 showed a significant enrichment of DEGs that are involved in DNA binding (Table 1). 314 Moreover, an analysis of functional modules formed by DEGs and their PPI partners 315 confirmed that gene expression regulation is affected (Fig. 2B, Supplementary Table 2). Yet,

316 based on ENCODE data 34 , we did not identify any transcription factor that could explain the 317 observed transcriptional profile. This is in accordance with the observation of Zhang *et al*. 318 that the disease-relevant impact of the 15q13.3 microdeletion is probably caused by the 319 combinatorial effects of several genes, rather than a single "master" gene. Our analysis 320 showed network-wide dysregulatory effects and explains why knockout models of singular 321 genes encompassed in the deletion could not fully recapitulate the phenotype $3-10$.

322 The GO analysis also revealed that DEGs show a significant enrichment in the 323 nervous system development category (Table 1). Indeed, we could show that the set of 324 dysregulated genes contained a significant proportion (*p*-value = 0.003) of genes which have 325 been related to monogenic NDD (Fig. 2C, Supplementary Table S1). The PPI functional 326 module analysis identified more specific developmental processes of the nervous system like 327 oligodendrocyte differentiation, axon and neuron projection development, as well as "positive 328 regulation of neuron death" to be affected (Fig. 2A, B, Supplementary Table S2). This aligns 329 with experimental data from Df[h15q13]/+ mice, which shows that both loss of *OTUD7A* and *CHRNA7* contribute to dendrite outgrowth defects $3,6$, and also with the recently described 331 involvement of $Klf13$ in the development of cortical interneurons. ¹⁰

332 To determine whether other DEGs silenced in the adult human brain might have 333 played a role in the nervous system development, we used the Allen Brain Atlas data, which 334 provides brain gene expression data during different developmental stages. 24 This showed 335 that a significant number of genes found to be differentially expressed in blood, but silenced 336 in the adult brain had maximum expression levels in the prenatal stage (Fig. 3).

337 Our data suggests that network-wide dysregulatory effects contribute to 15q13.3 338 microdeletion pathomechanisms. There are several lines of evidence that indicate a disturbed 339 nervous system development, suggesting the severity of 15q13.3 microdeletion individuals' 340 symptoms is probably determined in the early embryonic stages. The identification of 341 dysregulated genes clustering in inflammatory and immune pathways may be related to the 342 analyzed tissue, namely blood. However, since we identified components of the major 343 histocompatibility complex, class II to be dysregulated in the mouse brain, we cannot rule out 344 that immune insults could contribute to the increased vulnerability of 15q13.3 microdeletion-345 bearing offspring.

346 A major limitation of our study is the small cohort, in which individual-characteristic 347 gene expression levels, which were not caused by the microdeletion, can have a big impact on 348 the analysis. We attempted to circumvent this by comparing our data to the mouse model.

349 However, a larger cohort and potentially the analysis of an additional tissue like skin, could 350 further refine the analysis and unveil which gene network is mostly responsible for the 351 pathomechanism. This is crucial for directing future efforts to minimize the severity of the 352 phenotype.

353 **Acknowledgements**

354 We are grateful that our patients and their families agreed to participate in this study. 355 We thank Sandra Schinkel, Kathleen Lehmann, and Sophie Behrendt for their great technical 356 assistance and Rigo Schulz for server support. We are grateful to Torsten Schöneberg for his 357 input and help to draw Fig. 1.

358 **Author contributions**

359 MK performed gene expression analyses, contributed to the design of the study and 360 writing of the manuscript. AV and LB supported bioinformatic analyses and performed GO 361 enrichment analyses. MR performed wet lab work and contributed to the design of the study. 362 CCL performed PPI analyses and contributed to manuscript writing. PZ recruited patients, 363 performed phenotyping, and coordinated the genetic diagnosis. TB, AT, KP, and JH 364 performed genetic diagnosis and contributed to the writing of the manuscript. AK, AM, NS, 365 TL, KP, JRL, and AG contributed to analysis design, data interpretation, and writing of the 366 manuscript. RAJ and DLD designed the study, coordinated the contact to patients, contributed 367 to genetic diagnosis, gene expression analysis, and writing of the manuscript.

368 **Funding**

369 This study is funded by the Else Kröner-Fresenius-Stiftung 2020_EKEA.42 to DLD 370 and the German Research Foundation SFB 1052 project B10 to DLD and AG. DLD is funded 371 through the "Clinician Scientist Programm, Medizinische Fakultät der Universität Leipzig". 372 Open Access funding enabled and organized by Projekt DEAL.

373 **Data availability**

374 RNA sequencing reads and expression profiles have been submitted to the Gene 375 Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession number 376 GSE197903. The code used for analyzing data has been deposited under 377 https://github.com/akhilvelluva/15q13.3.

378

379

380 **References**

- 381 1. van Bon, B. W., Mefford, H. C. & de Vries, B. B. *15q13.3 Microdeletion*. 382 *GeneReviews®* (University of Washington, Seattle, 2015).
- 383 2. Lowther, C., Costain, G., Stavropoulos, D. J., Melvin, R., *et al.* Delineating the 384 15q13.3 microdeletion phenotype: A case series and comprehensive review of the 385 literature. *Genetics in Medicine* vol. 17 149–157 (2015).
- 386 3. Gillentine, M. A., Yin, J., Bajic, A., Zhang, P., *et al.* Functional Consequences of 387 CHRNA7 Copy-Number Alterations in Induced Pluripotent Stem Cells and Neural 388 Progenitor Cells. *Am. J. Hum. Genet.* **101**, 874–887 (2017).
- 389 4. Hoppman-Chaney, N., Wain, K., Seger, P. R., Superneau, D. W., *et al.* Identification of 390 single gene deletions at 15q13.3: Further evidence that CHRNA7 causes the 15q13.3 391 microdeletion syndrome phenotype. *Clin. Genet.* **83**, 345–351 (2013).
- 392 5. Yin, J., Chen, W., Chao, E. S., Soriano, S., *et al.* Otud7a Knockout Mice Recapitulate 393 Many Neurological Features of 15q13.3 Microdeletion Syndrome. *Am. J. Hum. Genet.* 394 **102**, 296–308 (2018).
- 395 6. Uddin, M., Unda, B. K., Kwan, V., Holzapfel, N. T., *et al.* OTUD7A Regulates 396 Neurodevelopmental Phenotypes in the 15q13.3 Microdeletion Syndrome. *Am. J. Hum.* 397 *Genet.* **102**, 278–295 (2018).
- 398 7. Ionita-Laza, I., Xu, B., Makarov, V., Buxbaum, J. D., *et al.* Scan statistic-based 399 analysis of exome sequencing data identifies FAN1 at 15q13.3 as a susceptibility gene 400 for schizophrenia and autism. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 343–348 (2014).
- 401 8. Florio, M., Albert, M., Taverna, E., Namba, T., *et al.* Human-specific gene 402 ARHGAP11B promotes basal progenitor amplification and neocortex expansion. 403 *Science (80-.).* **347**, 1465–1470 (2015).
- 404 9. Hori, T., Ikuta, S., Hattori, S., Takao, K., *et al.* Mice with mutations in Trpm1, a gene 405 in the locus of 15q13.3 microdeletion syndrome, display pronounced hyperactivity and 406 decreased anxiety-like behavior. *Mol. Brain* **14**, 1–16 (2021).
- 407 10. Malwade, S., Gasthaus, J., Bellardita, C., Andelic, M., *et al.* Identification of 408 Vulnerable Interneuron Subtypes in 15q13.3 Microdeletion Syndrome Using Single-409 Cell Transcriptomics. *Biol. Psychiatry* (2021) doi:10.1016/j.biopsych.2021.09.012.

- 410 11. Nilsson, S. R. O., Celada, P., Fejgin, K., Thelin, J., *et al.* A mouse model of the 411 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions 412 and attentional impairment. *Psychopharmacology (Berl).* **233**, 2151–2163 (2016).
- 413 12. Zhang, S., Zhang, X., Purmann, C., Ma, S., *et al.* Network Effects of the 15q13.3 414 Microdeletion on the Transcriptome and Epigenome in Human-Induced Neurons. *Biol.* 415 *Psychiatry* **89**, 497–509 (2021).
- 416 13. Solomon, E., Davis-Anderson, K., Hovde, B., Micheva-Viteva, S., *et al.* Global 417 transcriptome profile of the developmental principles of in vitro iPSC-to-motor neuron 418 differentiation. *BMC Mol. Cell Biol.* **22**, (2021).
- 419 14. Velluva, A., Radtke, M., Horn, S., Popp, B., *et al.* Phenotype-tissue expression and 420 exploration (PTEE) resource facilitates the choice of tissue for RNA-seq-based clinical 421 genetics studies. *BMC Genomics* **22**, 802 (2021).
- 422 15. Frésard, L., Smail, C., Ferraro, N. M., Teran, N. A., *et al.* Identification of rare-disease 423 genes using blood transcriptome sequencing and large control cohorts. *Nat. Med.* **25**, 424 911–919 (2019).
- 425 16. Curry, P. D. K., Broda, K. L. & Carroll, C. J. The Role of RNA-Sequencing as a New 426 Genetic Diagnosis Tool. *Curr. Genet. Med. Rep.* **9**, 13–21 (2021).
- 427 17. Zacher, P., Mayer, T., Brandhoff, F., Bartolomaeus, T., *et al.* The genetic landscape of 428 intellectual disability and epilepsy in adults and the elderly: a systematic genetic work-429 up of 150 individuals. *Genet. Med.* **23**, 1492–1497 (2021).
- 430 18. Gordon, A., Forsingdal, A., Klewe, I. V., Nielsen, J., *et al.* Transcriptomic networks 431 implicate neuronal energetic abnormalities in three mouse models harboring autism and 432 schizophrenia-associated mutations. *Mol. Psychiatry* **26**, 1520–1534 (2021).
- 433 19. Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., *et al.* STAR: Ultrafast universal 434 RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 435 20. Anders, S., Pyl, P. T. & Huber, W. HTSeq-A Python framework to work with high-436 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).
- 437 21. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and 438 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, (2014).
- 439 22. Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., *et al.* Controlling the false discovery 440 rate in behavior genetics research. in *Behavioural Brain Research* vol. 125 279–284

- 442 23. Marini, F. & Binder, H. PcaExplorer: An R/Bioconductor package for interacting with 443 RNA-seq principal components. *BMC Bioinformatics* **20**, (2019).
- 444 24. Grote, S., Prüfer, K., Kelso, J. & Dannemann, M. ABAEnrichment: An R package to 445 test for gene set expression enrichment in the adult and developing human brain. 446 *Bioinformatics* **32**, 3201–3203 (2016).
- 447 25. Team, R. C. R: A language and environment for statistical computing. (2013).
- 448 26. Grote, S. GOfuncR: Gene ontology enrichment using FUNC. *R Packag. version 1.5.1* 449 (2018).
- 450 27. Li, T., Wernersson, R., Hansen, R. B., Horn, H., *et al.* A scored human protein-protein 451 interaction network to catalyze genomic interpretation. *Nat. Methods* **14**, 61–64 (2016).
- 452 28. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., *et al.* Gene ontology: Tool for 453 the unification of biology. *Nature Genetics* vol. 25 25–29 (2000).
- 454 29. Carbon, S., Douglass, E., Dunn, N., Good, B., *et al.* The Gene Ontology Resource: 20 455 years and still GOing strong. *Nucleic Acids Res.* **47**, D330–D338 (2019).
- 456 30. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., *et al.* Gene set 457 enrichment analysis: A knowledge-based approach for interpreting genome-wide 458 expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**, 15545–15550 (2005).
- 459 31. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. Revigo summarizes and visualizes 460 long lists of gene ontology terms. *PLoS One* **6**, (2011).
- 461 32. Resnik, P. Semantic Similarity in a Taxonomy: An Information-Based Measure and its 462 Application to Problems of Ambiguity in Natural Language. *J. Artif. Intell. Res.* **11**, 463 95–130 (1999).
- 464 33. Tennekes, M. Package 'treemap' Type Package Title Treemap Visualization. (2021).
- 465 34. Roopra, A. MAgIC: A tool for predicting transcription factors and cofactors driving 466 gene sets using ENCODE data. *PLoS Comput. Biol.* **16**, e1007800 (2020).
- 467 35. Groenwold, R. H. H., Goeman, J. J. & Le Cessie, S. Multiple testing: When is many 468 too much? *Eur. J. Endocrinol.* **184**, E11–E14 (2021).
- 469 36. Xing, L., Kubik-Zahorodna, A., Namba, T., Pinson, A., *et al.* Expression of 470 human \Box specific ARHGAP11B in mice leads to neocortex expansion and increased

- 471 memory flexibility. *EMBO J.* **40**, (2021).
- 472 37. Jäger, E., Schulz, A., Lede, V., Lin, C.-C., *et al.* Dendritic Cells Regulate GPR34 473 through Mitogenic Signals and Undergo Apoptosis in Its Absence. *J. Immunol.* **196**, 474 2504–2513 (2016).
- 475 38. Le Duc, D., Lin, C. C., Popkova, Y., Yang, Z., *et al.* Reduced lipolysis in lipoma 476 phenocopies lipid accumulation in obesity. *Int. J. Obes.* **45**, 565–576 (2021).
- 477 39. Feng, W., Kawauchi, D., Körkel-Qu, H., Deng, H., *et al.* Chd7 is indispensable for 478 mammalian brain development through activation of a neuronal differentiation 479 programme. *Nat. Commun.* **8**, 1–14 (2017).
- 480 40. Karczewski, K. J., Francioli, L. C., Tiao, G., Cummings, B. B., *et al.* The mutational 481 constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 482 (2020).
- 483
- 484
- 485 **Figure legends**

486 **Fig. 1.** Overview of the 15q13.3 locus and symptoms associated with the 487 microdeletion A. Schematic representation of the 15q13.3 microdeletion region. Protein 488 coding genes within the region are shown beneath chromosome 15. The color legend 489 corresponds to the pLI score as a measure of loss-of-function deleteriousness 40 . Underlined 490 genes have been considered candidates that are responsible for the observed phenotypes 491 (*CHRNA7*^{3,4}, *OTUD7A*^{5,6}, *FAN1*⁷, *ARHGAP11B*⁸, *TRPM1*⁹, *KLF13*¹⁰)</sub> B. Individuals with 492 15q13.3 microdeletion display a heterogenous phenotype which can range from normal 493 development to severe intellectual disability (ID) or neurodevelopmental disorders (NDD). A 494 delineation of the phenotype based on 246 cases revealed predominantly neurologic 495 symptoms of which ID, epilepsy, and neuropsychiatric disorders are most prominent².

496 **Fig. 2.** Functional modules representation. A. Activated functional modules clusters in 497 individuals with 15q13.3 microdeletion. Functions that could influence nervous system 498 development are clustered in oligodendrocyte differentiation under the "cellular 499 differentiation" category. The size of the boxes is proportional to the activation level of the 500 module. B. Inactivated functional modules clusters in individuals with 15q13.3 microdeletion. 501 These include processes relevant for neuron development. The size of the boxes is

502 proportional to the inactivation level of the module. C. 252 of the DEGs are related to 503 monogenic neurodevelopmental disorders (NDD). The number of genes is significantly 504 higher than expected by chance (*p*-value binomial test = 0.003).

505 **Fig. 3.** Inquiry of DEGs which are not expressed in the adult brain cortex. Based on 506 the Allen Brain Atlas these genes show a significant enrichment for genes with highest 507 expression level in the prenatal stage (*p*-value adult *vs*. prenatal stage = 0.04).

508

509 **Table 1.** Enriched overrepresented GO terms in DEGs of 15q13.3 individuals. FWER:

510 family-wise error rate corrected p-value; #genes: number of DEGs involved in the function.

511 For genes included in the nodes refer to Supplementary Table S2.

512

513

В

Total=2,334 DEGs

Supplementary Fig. S1. Expression levels of genes located in the 15q13.3 microdeletion region. TPM (transcript per kilobase million mapped reads) values of gene expression levels are depicted for brain cortex tissue and whole blood. The dashed lines represent 1.5 TPM. Expression values were obtained from PTEE [\(https://bioinf.eva.mpg.de/PTEE/](https://bioinf.eva.mpg.de/PTEE/)).